Consistent with reports that abrogation of the immune evasive effects of oncogenic Kras can sensitize tumors to immune-checkpoint blockade (40), the combination of RMC-6236 with antiprogrammed death protein-1 (anti–PD-1, clone RMP1-14, rat IgG2a) resulted in durable complete tumor regressions in all animals (Fig. 4D; Supplementary Fig. S4D). This evidence concerns the gene KRAS and neoplasm.